

Iraq

Population 2016

37 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.2 (0.84–1.7)	3.3 (2.3–4.6)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.02 (0.01–0.02)
Incidence (includes HIV+TB)	16 (14–18)	43 (37–48)
Incidence (HIV+TB only)	0.016 (0.012–0.02)	0.04 (0.03–0.05)
Incidence (MDR/RR-TB)**	1.2 (0.88–1.5)	3.2 (2.4–4.1)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.84 (0.73–0.94)	5.7 (5–6.5)	6.6 (5.7–7.4)
Males	0.95 (0.83–1.1)	8.3 (7.3–9.4)	9.3 (8.1–10)
Total	1.8 (1.6–2)	14 (12–16)	16 (14–18)

TB case notifications, 2016	
Total cases notified	7 317
Total new and relapse	7 246
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	57%
- % pulmonary	59%
- % bacteriologically confirmed among pulmonary	62%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	46% (40–52)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.08 (0.05–0.11)

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy		0	

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			360 (270–440)
Estimated % of TB cases with MDR/RR-TB	6.1% (4.4–7.8)	24% (14–34)	
% notified tested for rifampicin resistance	78%	80%	5 699
MDR/RR-TB cases tested for resistance to second-line drugs			56
Laboratory-confirmed cases		MDR/RR-TB: 187, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 87, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	91%	8 183
Previously treated cases, excluding relapse, registered in 2015	82%	72
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014	49%	55
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017	
National TB budget (US\$ millions)	23
Funding source: 87% domestic, 7% international, 6% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically